Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine vs reduced-dose gemcitabine + nab-paclitaxel in frail patients with non-resectable pancreatic cancer
2021-005067-52Phase 2Active
- Sponsor
- Aalborg University Hospital
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in pancreatic cancer (PC) and pancreatic cancer (PDAC) comparing Gemcitabine full-dose monotherapy with Reduced-dose gemcitabine + nab-paclitaxel combination (2 arms). Primary endpoint: Progression-free survival. Started Nov 2021; status: active.
02
Drugs
gemcitabinepaclitaxel
03
Conditions
pancreatic cancer (PC)pancreatic cancer (PDAC)
Beyond the preview
Go deeper on 2021-005067-52.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005067-52.